You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 29, 2024

Claims for Patent: 6,756,033

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,756,033

Title:	Method for delivering benzindene prostaglandins by inhalation
Abstract:	A method of delivering benzindene prostaglandins to a patient by inhalation is discussed. A benzindene prostaglandin known as UT-15 has unexpectedly superior results when administered by inhalation compared to parenterally administered UT-15 in sheep with induced pulmonary hypertension.
Inventor(s):	Cloutier; Gilles (Chapel Hill, NC), Crow; James (Chapel Hill, NC), Wade; Michael (Chapel Hill, NC), Parker; Richard E. (Spring Hill, TN), Loyd; James E. (Nashville, TN)
Assignee:	United Therapeutics Corporation (Washington, DC)
Application Number:	10/212,149
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,756,033
Patent Claims:	1. A method of delivering to a mammal in need thereof a therapeutically effective amount of a benzindene prostaglandin comprising administering to the mammal by inhalation a formulation comprising droplets measuring less than 10 micrometers in diameter, wherein said droplets comprise a therapeutically effective amount of the benzindene prostaglandin. 2. The method of claim 1, wherein said the aerosolized form comprises droplets less than 10 micrometers in diameter, said droplets comprising said benzindene prostaglandin is 9-deoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor3,7-(1'3'-interphenylene)-1 3,14-dihydro-prostaglandin F.sub.1 in a suitable pharmacologically-acceptable liquid carrier. 3. The method of claim 1, wherein the mammal is a human. 4. The method of claim 1, wherein the formulation comprises a sustained release form of the benzindene prostaglandin. 5. The method of claim 1, wherein the administering of benzindene prostaglandin has no effect on heart rate. 6. A method of delivering to a mammal in need thereof a therapeutically effective amount of a benzindene prostaglandin comprising administering to the mammal by inhalation a powder formulation comprising particles measuring less than 10 micrometers in diameter, wherein said particles comprise a therapeutically effective amount of the benzindene prostaglandin. 7. The method of claim 6, wherein the benzindene prostaglandin is UT-15. 8. The method of claim 6, wherein the mammal is a human. 9. The method of claim 6, wherein the formulation comprises a sustained release form of the benzindene prostaglandin. 10. The method of claim 6, wherein the administering of the benzindene prostaglandin has no effect on heart rate.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.